Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 16

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 16
---
 the Merger? A: At the Effective Time, the board of directors of the combined company (Combined Company Board) will consist of seven directors and will be comprised of five members designated by Tvardi (Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk and Imran Alibhai), one member to be designated by Cara prior to Closing and one vacancy, to be designated by Tvardi if prior to the closing of the Merger or by the combined company if following the consummation of the Merger. The Combined Company Board will have an audit committee, a compensation committee and a nominating and corporate governance committee, in accordance with the rules of Nasdaq. All of Cara’s current directors other than the director to be designated by Cara prior to Closing are expected to resign from their positions as directors of Cara, effective upon the Effective Time. For a more complete description of the Combined Company Board, please see the section titled “ Management Following the Merger ” beginning on page 360of this proxy statement/prospectus. Q: Who will be the executive officers of Cara following the Merger? A: Immediately following the Merger, the executive management team of the combined company is expected to comprise the following individuals with such additional officers as may be added by the combined company:

| Name                        | ​ | ​ | Position with theCombined Company            | ​ | ​ | Current Position at Tvardi                   | ​ |
| Imran Alibhai, Ph.D.        | ​ | ​ | Chief Executive Officer and                  
 Director                                     | ​ | ​ | Chief Executive Officer and Director         | ​ |
| Dan Conn, J.D., M.B.A.      | ​ | ​ | Chief Financial Officer                      | ​ | ​ | Chief Financial Officer                      | ​ |
| John Kauh, M.D.             | ​ | ​ | Chief Medical Officer                        | ​ | ​ | Chief Medical Officer                        | ​ |
| Jeffrey Larson, Ph.D., DABT | ​ | ​ | Senior Vice President, Research &Development | ​ | ​ | Senior Vice President, Research &Development | ​ |
| Yixin “Joseph” Chen, Ph.D.  | ​ | ​ | Vice President, Chemistry,                   
 Manufacturing and Controls                   | ​ | ​ | Vice President, Chemistry,                   
 Manufacturing and Controls                   | ​ |

4

TABLE OF CONTENTS

Q:

As a stockholder of Cara, how does the Cara Board recommend that I vote?

A:

After careful consideration, the